- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.08. | Gain Therapeutics GAAP EPS of -$0.11 beats by $0.03 | 5 | Seeking Alpha | ||
| 11.08. | Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update | 533 | GlobeNewswire (Europe) | BETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| 16.07. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.07. | Gain Therapeutics plans phase 2 Parkinson's study in Q3 2026 | 1 | Investing.com | ||
| 16.07. | Gain Therapeutics plant Phase-2-Studie zu Parkinson für drittes Quartal 2026 | 1 | Investing.com Deutsch | ||
| 16.07. | Gain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update | 362 | GlobeNewswire (Europe) | BETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of... ► Artikel lesen | |
| GAIN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.07. | H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval | 3 | Investing.com | ||
| 29.06. | Gain Therapeutics, Inc.: Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease | 556 | GlobeNewswire (Europe) | IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy... ► Artikel lesen | |
| 25.06. | Gain Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Gain Therapeutics, Inc.: Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 2 | GlobeNewswire (USA) | ||
| 27.05. | Oppenheimer bestätigt "Outperform" für Gain Therapeutics | 6 | Investing.com Deutsch | ||
| 27.05. | Gain Therapeutics stock maintained at Outperform by Oppenheimer | 3 | Investing.com | ||
| 26.05. | Gain Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 26.05. | Gain Therapeutics presents phase 1b data on Parkinson's drug | 3 | Investing.com | ||
| 11.05. | Gain Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Gain Therapeutics übertrifft Verlustprognosen - Aktie legt zu | 3 | Investing.com Deutsch | ||
| 11.05. | Gain Therapeutics GAAP EPS of -$0.13 beats by $0.01 | 2 | Seeking Alpha |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,070 | -3,60 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,950 | +1,99 % | InflaRx: Revolutionäre Therapieansätze könnten alles verändern | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| IBIO | 1,163 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary... ► Artikel lesen | |
| GERON | 1,317 | +1,35 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 8,260 | +1,29 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 2,727 | +0,44 % | Myriad Genetics, Inc.: Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability | Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is... ► Artikel lesen | |
| MANNKIND | 3,395 | 0,00 % | MannKind-Aktie: Biotech-Chance mit neuen Wachstumstreibern | Die MannKind-Aktie steht nach zwei wichtigen FDA-Zulassungen vor einer neuen Wachstumsphase. Bei einer Marktkapitalisierung von rund 1,24 Milliarden US-Dollar könnte der Markt das langfristige Potenzial... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,064 | +0,66 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| IMMUNIC | 13,485 | -2,56 % | EQS-News: Immunic AG: Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Issuer: Immunic AG
/ Key word(s): Quarter Results
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
11.08.2026 / 12:30 CET/CEST
The... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 6,910 | -0,29 % | TD Cowen raises Iovance Biotherapeutics price target on sales outlook | ||
| MOLECULIN BIOTECH | 0,640 | 0,00 % | Moleculin Biotech, Inc.: Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial | Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AMLMIRACLE trial advancing toward planned 90-patient enrollment milestone in September... ► Artikel lesen | |
| GENPREX | 3,700 | +0,82 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| MESOBLAST | 1,560 | +2,33 % | Eli Lilly zahlt bis zu 7 Milliarden für Zelltherapie - warum jetzt auch bei Mesoblast der nächste große Test beginnt |
Das Unternehmen GAIN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,770 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GAIN THERAPEUTICS INC finden Sie auf Wallstreet Online.